Clear Gene

Clear Gene develops advanced RNA-based diagnostic solutions using genomics and machine learning. Their flagship product suite, including MICA Software™ and rapid test kits, enables more efficient and sensitive detection of residual solid tumor after treatment as well as high-throughput COVID‑19 testing. The company’s technology allows clinical laboratories to process more samples at lower cost using existing equipment. While their oncology solution addresses a major unmet need in detecting minimal residual disease in solid tumors like breast cancer—a space historically underserved compared to liquid tumors—their COVID-related products have been widely adopted by labs seeking faster turnaround with reliable results.